BioSpace News Archive

Suzhou’s Innovent Plans Capital Raise Followed by $200M IPO

Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200M in late 2018.

January 16, 2018
·
1 min read
Business

Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors

Ophthotech announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.

January 16, 2018
·
5 min read
Business

Foundation Medicine, Pfizer Pen Companion Diagnostics Deal

The partnership focuses on development, regulatory support and commercialization of companion diagnostics.

January 16, 2018
·
6 min read
Biotech Beach

MabVax Therapeutics Holdings Provides Business Strategy Update

With the assistance of Greenhill, MabVax is currently in advanced discussions with a variety of interested parties for potential multiple transaction proposals as well as continuing to identify new opportunities.

January 16, 2018
·
6 min read
Business

Impax to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018

The financial results and live webcast will be accessible through the Investor Relations section of the Company’s Web site at http://investors.impaxlabs.com.

January 16, 2018
·
1 min read
Genetown

Hologic Announces Offering of $1B of Senior Notes

The additional 2025 notes will be issued under the indenture dated October 10, 2017 that governs Hologic’s 4.375% senior notes due 2025.

January 16, 2018
·
3 min read
Drug Development

Constellation Pharmaceuticals Announces Initiation of Phase Ib/II Study of CPI-1205 in Combination with Checkpoint Inhibitors

Constellation Pharmaceuticals announced it has initiated a Phase 1b/2 clinical trial to evaluate CPI-1205, a small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2).

January 16, 2018
·
3 min read
Drug Development

Ophthotech Announces First Patient Enrolled in the Phase IIb Clinical Trial of Zimura, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease (STGD1).

January 16, 2018
·
6 min read
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies

Tenax announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

January 16, 2018
·
4 min read
Business

OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes to Board of Directors

The Company’s Board appointed Mayes on Friday, January 12, 2018.

January 16, 2018
·
5 min read